🦊/Companies

NaluBio, Inc.

San Francisco, US · Founded 2019 · Delaware corporation · 14 employees on LinkedIn · 4 known investors

Find your way into NaluBio, Inc.

230 people in our graph share verified history with the NaluBio, Inc. team — schools, employers, funds. One of them is your warm intro.

Petra Meyerunlockedknows Caitlyn Krebs · together at WBL (Women Business Leaders of the US Health Care Industry Foundation) (overlapped)
×4knows the team · via Playground Global
knows the team · via Analyte Health
×3knows the team · via Springboard Enterprises
×3knows the team · via Leaders In Tech

Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.

Founders & leadership

NaluBio, Inc. was founded in 2019 by Caitlyn Krebs, Phyllis Whiteley, and Randall Ussery.

CKCaitlyn Krebs
Caitlyn KrebsinCo-founder + CEOCaitlyn Krebs is co-founder and CEO of Nalu Bio, an AI-powered drug discovery company developing therapeutics for inflammatory, immune, and metabolic diseases including chronic pain, sleep disorders, and endometriosis. She has held leadership roles at multiple biotech companies spanning AI-driven drug discovery, diabetes prevention, Alzheimer's detection, and cancer diagnostics over the past 20+ years.
PWPhyllis Whiteley
Phyllis WhiteleyinCo-founder + Board MemberPhyllis Whiteley holds a BA in Chemistry and PhD in Pharmacology from Washington University in St. Louis. She has held executive and board roles across venture capital, biotech, and pharma, including positions at Roche, Perlegen, Merck, and MDV, where she helped build companies including Verinata Health (acquired by Illumina), and previously co-founded Anaphore with 5AM Ventures.
RU
Randall UsseryCo-founder + Board Member
HG
Howard GoodwinNamed on SEC filing

Investors · 4

Reported raises · per SEC filings

Form D private placements

$4.8M disclosed across 1 round · 2023

$4.8MraisedMar 2023 · 11 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Phyllis E. WhiteleyExecutive Officer, Director
  • Howard GoodwinDirector
  • Randall S. UsseryDirector
  • Caitlyn KrebsExecutive Officer, Director
Offering amount
$17.1M
Amount sold
$4.8M
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Companies competing with NaluBio, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does NaluBio, Inc. do?
Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.
Who founded NaluBio, Inc.?
NaluBio, Inc. was founded by Caitlyn Krebs, Phyllis Whiteley, Randall Ussery in 2019.
Who are NaluBio, Inc.'s investors?
NaluBio, Inc.'s investors include Bonaventure Equity, LLC, Flybridge Capital Partners, Portfolia, Golden Seeds.
How much funding has NaluBio, Inc. raised?
NaluBio, Inc. has disclosed $4.8M raised across 1 round.
Where is NaluBio, Inc. headquartered?
NaluBio, Inc. is headquartered in San Francisco, US.